Journal
JOURNAL OF PERINATOLOGY
Volume 41, Issue 9, Pages 2134-2140Publisher
SPRINGERNATURE
DOI: 10.1038/s41372-021-01132-4
Keywords
-
Categories
Funding
- National Institute of Health Research, UK
- Medical Research Council, UK
- NIHR Biomedical Research Centre
Ask authors/readers for more resources
The study suggests that erythropoietin monotherapy may reduce the risk of death or neuro-disability in infants with neonatal encephalopathy in low-middle income countries.
Objective We examined whether erythropoietin monotherapy improves neurodevelopmental outcomes in near-term and term infants with neonatal encephalopathy (NE) in low-middle income countries (LMICs). Methods We searched Pubmed, Embase, and Web of Science databases to identify studies that used erythropoietin (1500-12,500 units/kg/dose) or a derivative to treat NE. Results Five studies, with a total of 348 infants in LMICs, were retrieved. However, only three of the five studies met the primary outcome of death or neuro-disability at 18 months of age or later. Erythropoietin reduced the risk of death (during the neonatal period and at follow-up) or neuro-disability at 18 months or later (p < 0.05). Death or neuro-disability occurred in 27.6% of the erythropoietin group and 49.7% of the comparison group (risk ratio 0.56 (95% CI: 0.42-0.75)). Conclusion The pooled data suggest that erythropoietin monotherapy may improve outcomes after NE in LMICs where therapeutic hypothermia is not available.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available